睿智醫藥(300149.SZ):睿昀投資及其一致行動人已減持506.76萬股
格隆匯1月14日丨睿智醫藥(300149.SZ)公佈,2022年1月14日,公司收到睿昀投資及其一致行動人睿釗投資的《減持計劃實施完畢的吿知函及致歉説明》,截止公吿披露日,睿昀投資及其一致行動人睿釗投資上述減持計劃已實施完畢,其於減持期間合計減持506.76萬股,佔公司總股本的1.01%。
此次減持計劃預披露的減持數量為不超過499萬股,實際減持數量超出減持計劃7.76萬股,佔公司總股本的 0.0155%,對應減持金額126.81萬元。
上述情況為當事人操作失誤,非主觀故意,睿昀投資及其一致行動人睿釗投資已深刻認識其嚴重性,在意識到上述情況違反減持規定後,其主動向公司報吿,並進行了深刻反省,其對本次操作給公司和市場帶來的不良影響,向廣大投資者致以誠摯的歉意。今後將加強對持有公司股票證券賬户的管理,信守承諾,堅決杜絕此類件的再次發生。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.